// App-Quantinova.ai

2232 : Understanding the Patient‐Perceived Impact of Nonalcoholic Steatohepatitis: Raising the Volume on a Silent Disease

Researchers

Presenter

  • Lynda C. Doward

Principal Investigators

  • Maria-Maadalena Balp

  • James Twiss

  • Christina Slota

  • Donna Cryer

  • A. Langford

  • Rebecca Collen

  • Neetu Agashivala

  • Clifford Brass

  • Quentin M. Anstee

  • Arun Sanyal

Medical Centers

  • Patient Centered Outcomes Assessment, RTI‐ Health Solutions, Manchester, United Kingdom

  • Novartis AG, Basel, Switzerland

  • Patient Centered Outcomes Assessment, RTI‐Health Solutions, Raleigh‐Durham, NC

  • Global Liver Institute, Washington, DC

  • British Liver Trust, Bournemouth, United Kingdom

  • Medical Coll of Virginia, Virginia Commonwealth Univ, Richmond, VA

  • Novartis Pharmaceutical Corporation, East Hanover, NJ

  • Institute of Cellular Medicine, Newcastle University, Newcastle Upon Tyne, United Kingdom

Locations

  • United Kingdom

  • Switzerland

  • United States

Companies

  • Novartis AG

Study Components

Therapeutic Area

  • Gastroenterology (GU)

Disease

  • Nonalcoholic steatohepatitis

Biomarkers

  • N/A

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved